WHO’s Working for Health 2022–2030 Action Plan

By Staff Writer

February 6, 2023

Introduction:

Achieving universal health care (UHC) is a World Health Organisation (WHO) strategic priority, with the goal of 1 billion more people benefitting from universal health coverage by 2025. This publication on health and care workforce planning provides a rationale for the related actions of the Working for Health progression model.

The Need for Planning and Financing:

Planning and financing are integral to the efficient and cost-effective development of health and care workforce policies. Their importance is particularly evident in low- and middle-income countries (LMICs), where technical and institutional capacity to support planning and financing is often inadequate. In such strained economic environments, building this capacity is a priority.

The Working for Health Model:

The Working for Health progression model offers a pathway for countries facing critical workforce challenges to progressively optimise, build, and strengthen their workforce. The model focuses on three key themes: planning and financing, education and employment, and protection and performance.

The Current Context:

The COVID-19 pandemic has highlighted the need for effective planning and strategic financing in the health and care workforce. LMICs face challenges such as building labour market demand for health and care workers, mobilising sufficient and sustainable revenue, and attracting and retaining workers within the health system.

Policy Landscape:

The WHO Global Strategy presents a range of policy options to advance the health and care workforce agenda. These options emphasise the need to strengthen the integration and synergy of health workforce policy with broader development strategies.

Challenges:

The COVID-19 pandemic has had a devastating impact on economies worldwide. Financial resources allocated to health and care workforce are constrained by the economic crises facing many countries. In addition, many countries lack the technical and institutional capacity to translate evidence-based information into policy development and implementation.

Future Directions:

The challenges faced by the health and care workforce require strategic planning and financing. Investment in the health and care workforce is critical in emergency and disaster risk management, building the resilience of the health system to shocks and surges in demand.

Conclusion:

The health and care workforce is a vital component of the healthcare ecosystem. As such, it is essential to invest in strategic planning and financing to ensure its growth and sustainability. By doing so, we can ensure a resilient health system capable of meeting the needs of populations worldwide.

 

 

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.